The CJC-1295 (no DAC) & Ipamorelin Stack: A Synergistic Protocol for Growth Hormone Optimization

CJC-1295 without DAC (Drug Affinity Complex) is a short-acting growth hormone-releasing hormone (GHRH) analog known for stimulating natural pulsatile GH release. Unlike the DAC version, this form of CJC-1295 promotes physiologically-timed growth hormone spikes, aligning with the body’s natural rhythms. It is often combined with GHRP peptides like Ipamorelin to maximize GH output, making it highly valuable in research on recovery, fat loss, and anti-aging

CJC-1295 (No DAC) offers a flexible and physiologically-aligned tool for researchers focused on hormonal optimization, physical recovery, and metabolic health.

Key Benefits:

• Natural GH Pulses: Encourages more physiologic growth hormone release patterns.
• Improved Recovery: Supports tissue regeneration, especially when stacked with GHRPs.
• Fat Loss & Lean Mass Support: Increases GH and IGF-1, aiding fat metabolism and muscle maintenance.
• Sleep & Cellular Repair: Enhances restorative processes typically active during deep sleep.
• Short-Acting Precision: Allows better timing control in GH research protocols.

What is the combination Ipamorelin / CJC-1295 NO DAC

Ipamorelin is a selective GHRP-agonist that stimulates growth hormone release via the ghrelin receptor. CJC-1295 without DAC (Drug Affinity Complex) is a modified GHRH analog that promotes pulsatile release of GH without prolonging its half-life. Their combination is being studied as a synergistic method to influence GH production in a natural rhythm without suppressing endogenous secretion.

How their injectable combination works

When administered by sc or im injection, Ipamorelin binds to the ghrelin receptor in the pituitary gland, while CJC-1295 NO DAC stimulates the release of GHRH. The combination results in a synergistic GH pulse that mimics natural secretory patterns. The advantage of this combination is the absence of prolactinemic side effects and a lower risk of receptor desensitization.

Effects studied

• Increase in GH and IGF-1 levels: Observed in both animals and humans when monitoring growth markers.
• Regeneration: Supporting the repair of muscles, tendons and joints in damaged tissues.
• Sleep cycles: GH is associated with deep sleep and pulses can support sleep architecture.
• Neuroendocrine effects: Possible effect on memory, motivation, and hypothalamic-pituitary axis function.
• Recombination with other GHRPs: Frequently studied protocols with synergistic effects.

Dosage in studies

• Dosage: 100 – 300 μg of each ingredient
• Form: subcutaneous injection
• Frequency: 1 – 3 times a day (morning, after training, before bed)
• Duration: 4 – 12 week cycles in monitored protocols

Possible side effects

• Rarely, itching or tenderness at the injection site
• Possible temporary water retention
• Appetite changes (especially when combined with GHRP-6)